A quality detection process for Ogilvy sodium and magnesium compound chewable tablets and its application
By preparing specific solutions in Omeme sodium magnesium compound chewable tablet quality detection and combining chromatography and mass spectrometry technology, the problems of low accuracy and precision in existing detection technologies are solved, and more efficient quality control and detection accuracy are achieved.
Patent Information
- Application Number
- CN202410096811.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-24
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-01-24
AI Technical Summary
The existing Omeme sodium magnesium compound chewable tablet quality detection process cannot effectively avoid the influence of the detection background and the drug itself, resulting in low detection accuracy and precision, affecting quality control.
Using a detection process including sample preparation, detection and precision verification, the linear solution, sample mother liquor, sample solution, quantitative limited solution and accuracy solution are prepared, and the polymer selectively adsorbs omeprazole impurities and combined with Chromatography and mass spectrometry techniques perform detection, optimizing detection procedures to improve detection accuracy and efficiency.
It greatly improves the accuracy and precision of impurity detection of Omemeso sodium magnesium compound chewable tablets, avoids solution precipitation and wall sticking, protects the detection instrument, reduces maintenance costs, and provides a more efficient quality control method.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present application relates to the field of drug testing, and in particular to a quality testing process for a sodium-magnesium compound chewable tablet and its application. Background Art
[0002] Omeprazole is a drug mainly used for duodenal ulcer and Zollinger-Ellison syndrome. It can be used for the treatment of acute bleeding from peptic ulcer when injected intravenously. It can also be used in combination with drugs such as amoxicillin and clindamycin to treat Helicobacter pylori infection-related diseases.
[0003] Omeprazole sodium magnesium compound chewable tablets are tablets made of omeprazole, sodium bicarbonate and magnesium hydroxide as the main drugs. In order to ensure the quality of the drug and the safety and effectiveness of clinical drug use, it is necessary to check the impurities in the drug. However, in the existing quality / impurity detection process, it is impossible to effectively avoid the influence of the detection background and other components of the drug itself, and there is still a phenomenon of low accuracy and precision, which has brought uncontrollable influences to the quality control of Omeprazole sodium magnesium compound chewable tablets.
[0004] Therefore, in order to solve the above problems, the present application provides a quality inspection process for omeprazole sodium-magnesium compound chewable tablets, which can effectively avoid the above influences and greatly improve the accuracy and efficiency of quality inspection. Summary of the invention
[0005] In order to solve the above problems, the first aspect of the present application provides a quality detection process for omeprazole sodium-magnesium compound chewable tablets, which includes the following steps: S1: preparation of sample solution; S2: detection of sample solution; S3: precision verification test.
[0006] As a preferred solution, the sample solution at least includes a linear solution, a sample mother solution, a sample solution, a quantitative limit solution, and an accuracy solution.
[0007] As a preferred solution, the preparation method of the linear solution is: take the impurity control solution separately, and use organic solvent to make up the volume, and prepare the linear solution according to the linear gradient.
[0008] As a preferred solution, the concentration of the impurity control solution is 8-15 mg / L.
[0009] As a preferred solution, the concentration of the impurity control solution is 10 mg / L.
[0010] As a preferred embodiment, the impurities are omeprazole impurity I-Sdn, omeprazole impurity II-Snn, omeprazole impurity III-Sss and omeprazole impurity IV-Sds.
[0011] As a preferred solution, the linear gradient of the linear solution is as shown in Table 1 below:
[0012] Table 1
[0013]
[0014] As a preferred solution, the impurity concentration of the linear solution is 20-100 μg / L.
[0015] As a preferred solution, the impurity concentrations of the linear solutions are 20, 40, 60, 80, and 100 μg / L, respectively.
[0016] As a preferred solution, the method for preparing the sample mother solution comprises the following steps: accurately weighing the Ogilvy sodium magnesium compound chewable tablets and placing them in a volumetric bottle, adding a mixed solvent to dissolve and dilute to a fixed volume to obtain a sample mother solution.
[0017] As a preferred solution, the method for preparing the sample solution comprises the following steps: S1: adding polymer MIP to the sample mother solution; OI-I-Sdn After adsorption, take out the polymer MIP OI-I-Sdn ; S2:, eluted polymer MIP OI-I-Sdn , desorb by shaking, blow dry with nitrogen, and then re-dissolve and fix to volume with a mixed solvent to obtain a sample solution.
[0018] As a preferred solution, the MIP OI-I-Sdn The preparation method comprises the following steps: S1: 4-vinylpyridine is used as a functional monomer and omeprazole impurity I-Sdn is used as a template molecule, and the two are coordinated by Co(Ⅱ) to form a polymer monomer M 4-VP-Co(Ⅱ)-OI-I-Sdn ; S2: polymerized monomer M 4-VP-Co(Ⅱ)-OI-I-Sdn The polymerization reaction is carried out with divinylbenzene in the presence of azobisisobutyronitrile as an initiator, and the polymer product is eluted with a solvent to obtain a polymer MIP containing the omeprazole impurity I-Sdn molecular imprint. OI-I-Sdn ; The solvent is a mixed solvent of methanol and acetic acid.
[0019] As a preferred solution, the volume ratio of methanol to acetic acid is (6-7):(3-4).
[0020] As a preferred solution, the volume ratio of methanol to acetic acid is 7:3.
[0021] As a preferred embodiment, the mixed solvent is a mixed solvent of sodium bicarbonate solution and acetonitrile; the volume ratio of the sodium bicarbonate solution to acetonitrile is (5-6): (4-5).
[0022] As a preferred solution, the volume ratio of the sodium bicarbonate solution to acetonitrile is 6:4.
[0023] As a preferred solution, the concentration of the sodium bicarbonate solution is 0.01 mol / L.
[0024] As a preferred solution, the method for preparing the quantitative limit solution includes the following steps: S1: taking the sample mother solution into a container, adding the impurity control solution, and then adding n-hexane, shaking and standing to separate the organic phase; S2: adding anhydrous magnesium sulfate and taking the supernatant.
[0025] As a preferred solution, the spiked concentration of impurities in the quantitative limit solution is 10-30 μg / L.
[0026] As a preferred solution, the spiked concentration of impurities in the quantitative limit solution is 15-25 μg / L.
[0027] As a preferred solution, the spiked concentration of impurities in the quantitative limit solution is 20 μg / L.
[0028] As a preferred solution, the method for preparing the accuracy solution includes the following steps: S1: taking the sample mother solution into a container, adding the impurity reference solution, and then adding n-hexane, shaking and standing to separate the organic phase; S2: adding anhydrous magnesium sulfate and taking the supernatant.
[0029] As a preferred solution, the spiked concentration of impurities in the accuracy solution is 30-45 μg / L.
[0030] As a preferred solution, the spiked concentration of impurities in the accuracy solution is 35-40 μg / L.
[0031] As a preferred solution, the spiked concentration of impurities in the accuracy solution is 40 μg / L.
[0032] As a preferred solution, the temperature rising program in the sample detection process is 100°C to 240°C at a rate of 15-20°C / min, and maintained for 1-3 minutes; then raised to 300°C at a rate of 20-25°C / min, and maintained for 3-8 minutes.
[0033] As a preferred solution, the chromatographic parameters in the sample detection process are shown in Table 2 below:
[0034] Table 2
[0035]
[0036] As a preferred solution, the mass spectrometry parameters in the sample detection process are shown in Table 3 below:
[0037] Table 3
[0038]
[0039] As a preferred solution, the precision verification test includes linearity, accuracy, limit of quantitation, and precision-repeatability tests.
[0040] As a preferred solution, the linear detection process is to take a linear solution for sampling and analysis, and the instrument automatically calculates the regression equation to obtain the correlation coefficient of the equation.
[0041] As a preferred solution, the accuracy detection process is to take sample solution and accuracy solution for injection analysis, and calculate the recovery rate and relative error.
[0042] As a preferred solution, the quantitative limit detection process is to sample and analyze the quantitative limit solution, and calculate the recovery rate and relative error.
[0043] A second aspect of the present application provides an application of the above-mentioned quality detection process for the omeprazole sodium-magnesium compound chewable tablets, including application of the quality detection process for the omeprazole sodium-magnesium compound chewable tablets in the quality detection process for drug chewable tablets.
[0044] Beneficial effects:
[0045] 1. This application provides a quality detection process for omeprazole sodium-magnesium compound chewable tablets, which can avoid the influence of detection background and other components of the drug itself in existing detection technologies, greatly improve the accuracy and precision of impurity detection of omeprazole sodium-magnesium compound chewable tablets, and bring a new direction for quality control of omeprazole sodium-magnesium compound chewable tablets.
[0046] 2. The present application provides a quality inspection process for omeprazole sodium and magnesium compound chewable tablets, which can selectively adsorb omeprazole impurity I-Sdn, omeprazole impurity II-Snn, omeprazole impurity III-Sss and omeprazole impurity IV-Sds through synthetic polymers, and use them as samples for inspection, thereby greatly improving the quality inspection accuracy and inspection efficiency.
[0047] 3. The present application provides a quality inspection process for the sodium-magnesium compound chewable tablets. The sample solution preparation method in the scheme can effectively avoid the precipitation and wall sticking of the solution, thereby effectively protecting the detection instrument and reducing the maintenance cost of the instrument while improving the detection accuracy.
[0048] 4. This application provides a quality inspection process for omeprazole sodium magnesium compound chewable tablets. This application provides a new direction for drug quality inspection, which can greatly improve the accuracy of inspection while ensuring the inspection efficiency. The operation method is not more complicated than the ordinary method. On the contrary, the single impurity can be more specifically inspected by designing the inspection process. DETAILED DESCRIPTION
[0049] The following will further explain and demonstrate the technical solutions in the above invention content of this application in the form of specific implementation schemes. The following embodiments are only practical examples used to illustrate and explain the contents of the technical solutions in the specification, and should not limit the scope of the claims to be protected by this application. All technical products based on the technical solutions described in the invention content of this application should be included in the scope to be protected by this application.
[0050] In the following examples, unless otherwise specified, the raw materials are all commercially available products, or can be prepared by methods well known to those skilled in the art.
[0051] Example 1
[0052] Example 1 The first aspect provides a quality detection process for a sodium-magnesium compound chewable tablet, the process comprising the following steps: S1: sample solution preparation; S2: sample solution detection; S3: precision verification detection.
[0053] The sample solution includes: linear solution, sample mother solution, sample solution, quantitative limit solution, and accuracy solution.
[0054] The preparation method of the linear solution is: take the impurity control solution separately, and make up the volume with an organic solvent, and prepare the linear solution according to the linear gradient.
[0055] The concentration of the impurity control solution was 10 mg / L.
[0056] The impurities are omeprazole impurity I-Sdn, omeprazole impurity II-Snn, omeprazole impurity III-Sss and omeprazole impurity IV-Sds.
[0057] The linear gradient of the linear solution is shown in the following table:
[0058]
[0059] The impurity concentrations of the linear solutions were 20, 40, 60, 80, and 100 μg / L, respectively.
[0060] The method for preparing the sample mother solution comprises the following steps: accurately weighing the Ogilvy sodium magnesium compound chewable tablets and placing them in a volumetric flask, adding a mixed solvent to dissolve and dilute to 500 mL to obtain the sample mother solution, and preparing 3 portions in parallel using the same method.
[0061] The method for preparing the sample solution comprises the following steps: S1: adding polymer MIP to the sample mother solution OI-I-Sdn After adsorption, take out the polymer MIP OI-I-Sdn ; S2:, eluted polymer MIP OI-I-Sdn, desorb by shaking, blow dry with nitrogen, then re-dissolve with mixed solvent and make up to 500 mL to obtain sample solution, and prepare 3 parts in parallel with the same method.
[0062] MIP OI-I-Sdn The preparation method comprises the following steps: S1: adding 1.2 g of omeprazole impurity I-Sdn and 240 mg of cobalt chloride to 10 mL of chloroform, shaking for 10 min, standing for 1 h, adding 380 mg of 4-vinylpyridine to the chloroform solution, shaking for 3 min, standing for 0.5 h, and obtaining a polymerized monomer M 4-VP-Co(Ⅱ)-OI-I-Sdn ; S2: Add 4.9g of divinylbenzene and 0.1g of azobisisobutyronitrile to the chloroform solution, shake for 0.5h, pass nitrogen for 0.5h, seal the tube in vacuum, and then polymerize at 60°C for 5h. The polymer product is sieved through a 400-mesh sieve, and the omeprazole impurity I-Sdn molecules are eluted with a solvent until no omeprazole impurity I-Sdn molecules are detected in the washing liquid. Then, the solid product is vacuum dried at 50°C to constant weight to obtain; wherein the solvent is a mixed solvent of methanol and acetic acid.
[0063] The volume ratio of methanol to acetic acid is 7:3.
[0064] The mixed solvent is a mixed solvent of disodium bicarbonate solution and acetonitrile; the volume ratio of the disodium bicarbonate solution to acetonitrile is 6:4.
[0065] The concentration of sodium bicarbonate solution is 0.01 mol / L.
[0066] The preparation method of the quantitative limit solution includes the following steps: S1: taking the sample mother solution into a container, adding the impurity control solution, and then adding n-hexane, shaking and standing to separate the organic phase; S2: adding anhydrous magnesium sulfate, taking the supernatant, and preparing 3 portions in parallel with the same method.
[0067] The spiked concentration of impurities in the quantification limit solution was 20 μg / L.
[0068] The preparation method of the accuracy solution includes the following steps: S1: taking the sample mother solution into a container, adding the impurity reference solution, and then adding n-hexane, shaking and standing to separate the organic phase; S2: adding anhydrous magnesium sulfate, taking the supernatant, and preparing 6 portions in parallel with the same method.
[0069] The spike concentration of impurities in the accuracy solution was 40 μg / L.
[0070] The temperature was raised from 100°C at a rate of 20°C / min to 240°C and maintained for 2 min; then raised to 300°C at a rate of 30°C / min and maintained for 6 min.
[0071] The chromatographic parameters during sample testing are shown in the following table:
[0072]
[0073] The parameters of mass spectrometry during sample detection are shown in the following table:
[0074]
[0075] Precision verification tests include linearity, accuracy, limit of quantitation, and precision-repeatability tests.
[0076] The linear detection process is to take a linear solution for sampling and analysis, and the instrument automatically calculates the regression equation to obtain the correlation coefficient of the equation.
[0077] The accuracy test process is to take sample solution and accuracy solution for analysis, and calculate the recovery rate and relative error.
[0078] The quantitative limit detection process is to take the quantitative limit solution for sampling and analysis, and calculate the recovery rate and relative error.
[0079] Example 2
[0080] Example 2 The first aspect provides a quality detection process for a sodium-magnesium compound chewable tablet, the process comprising the following steps: S1: sample solution preparation; S2: sample solution detection; S3: precision verification detection.
[0081] The sample solution includes: linear solution, sample mother solution, sample solution, quantitative limit solution, and accuracy solution.
[0082] The preparation method of the linear solution is: take the impurity control solution separately, and make up the volume with an organic solvent, and prepare the linear solution according to the linear gradient.
[0083] The concentration of the impurity control solution was 10 mg / L.
[0084] The impurities are omeprazole impurity I-Sdn, omeprazole impurity II-Snn, omeprazole impurity III-Sss and omeprazole impurity IV-Sds.
[0085] The linear gradient of the linear solution is shown in the following table:
[0086]
[0087] The impurity concentrations of the linear solutions were 20, 40, 60, 80, and 100 μg / L, respectively.
[0088] The method for preparing the sample mother solution comprises the following steps: accurately weighing the Ogilvy sodium magnesium compound chewable tablets and placing them in a volumetric flask, adding a mixed solvent to dissolve and dilute to 500 mL to obtain the sample mother solution, and preparing 3 portions in parallel using the same method.
[0089] The method for preparing the sample solution comprises the following steps: S1: adding polymer MIP to the sample mother solution OI-I-Sdn After adsorption, take out the polymer MIP OI-I-Sdn ; S2:, eluted polymer MIP OI-I-Sdn , desorb by shaking, blow dry with nitrogen, then re-dissolve with mixed solvent and make up to 500 mL to obtain sample solution, and prepare 3 parts in parallel with the same method.
[0090] MIP OI-I-Sdn The preparation method comprises the following steps: S1: adding 1.2 g of omeprazole impurity I-Sdn and 240 mg of cobalt chloride to 10 mL of chloroform, shaking for 10 min, standing for 1 h, adding 380 mg of 4-vinylpyridine to the chloroform solution, shaking for 3 min, standing for 0.5 h, and obtaining a polymerized monomer M 4-VP-Co(Ⅱ)-OI-I-Sdn ; S2: Add 4.9g of divinylbenzene and 0.1g of azobisisobutyronitrile to the chloroform solution, shake for 0.5h, pass nitrogen for 0.5h, seal the tube in vacuum, and then polymerize at 60°C for 5h. The polymer product is sieved through a 400-mesh sieve, and the omeprazole impurity I-Sdn molecules are eluted with a solvent until no omeprazole impurity I-Sdn molecules are detected in the washing liquid. Then, the solid product is vacuum dried at 50°C to constant weight to obtain; wherein the solvent is a mixed solvent of methanol and acetic acid.
[0091] The volume ratio of methanol to acetic acid is 6:4.
[0092] The mixed solvent is a mixed solvent of disodium bicarbonate solution and acetonitrile; the volume ratio of the disodium bicarbonate solution to acetonitrile is 5:5.
[0093] The concentration of sodium bicarbonate solution is 0.01 mol / L.
[0094] The preparation method of the quantitative limit solution includes the following steps: S1: taking the sample mother solution into a container, adding the impurity control solution, and then adding n-hexane, shaking and standing to separate the organic phase; S2: adding anhydrous magnesium sulfate, taking the supernatant, and preparing 3 portions in parallel with the same method.
[0095] The spiked concentration of impurities in the quantification limit solution was 20 μg / L.
[0096] The preparation method of the accuracy solution includes the following steps: S1: taking the sample mother solution into a container, adding the impurity reference solution, and then adding n-hexane, shaking and standing to separate the organic phase; S2: adding anhydrous magnesium sulfate, taking the supernatant, and preparing 6 portions in parallel with the same method.
[0097] The spike concentration of impurities in the accuracy solution was 40 μg / L.
[0098] The temperature was raised from 100°C at a rate of 20°C / min to 240°C and maintained for 2 min; then raised to 300°C at a rate of 30°C / min and maintained for 6 min.
[0099] The chromatographic parameters during sample testing are shown in the following table:
[0100]
[0101] The parameters of mass spectrometry during sample detection are shown in the following table:
[0102]
[0103] Precision verification tests include linearity, accuracy, limit of quantitation, and precision-repeatability tests.
[0104] The linear detection process is to take a linear solution for sampling and analysis, and the instrument automatically calculates the regression equation to obtain the correlation coefficient of the equation.
[0105] The accuracy test process is to take sample solution and accuracy solution for analysis, and calculate the recovery rate and relative error.
[0106] The quantitative limit detection process is to take the quantitative limit solution for sampling and analysis, and calculate the recovery rate and relative error.
[0107] Example 3
[0108] Example 3 The first aspect provides a quality detection process for omeprazole sodium-magnesium compound chewable tablets, the process comprising the following steps: S1: sample solution preparation; S2: sample solution detection; S3: precision verification detection.
[0109] The sample solution includes: linear solution, sample mother solution, sample solution, quantitative limit solution, and accuracy solution.
[0110] The preparation method of the linear solution is: take the impurity control solution separately, and make up the volume with an organic solvent, and prepare the linear solution according to the linear gradient.
[0111] The concentration of the impurity control solution was 10 mg / L.
[0112] The impurities are omeprazole impurity I-Sdn, omeprazole impurity II-Snn, omeprazole impurity III-Sss and omeprazole impurity IV-Sds.
[0113] The linear gradient of the linear solution is shown in the following table:
[0114]
[0115] The impurity concentrations of the linear solutions were 20, 40, 60, 80, and 100 μg / L, respectively.
[0116] The method for preparing the sample mother solution comprises the following steps: accurately weighing the Ogilvy sodium magnesium compound chewable tablets and placing them in a volumetric flask, adding a mixed solvent to dissolve and dilute to 500 mL to obtain the sample mother solution, and preparing 3 portions in parallel using the same method.
[0117] The method for preparing the sample solution comprises the following steps: S1: adding polymer MIP to the sample mother solution OI-I-Sdn After adsorption, take out the polymer MIP OI-I-Sdn ; S2:, eluted polymer MIP OI-I-Sdn , desorb by shaking, blow dry with nitrogen, then re-dissolve with mixed solvent and make up to 500 mL to obtain sample solution, and prepare 3 parts in parallel with the same method.
[0118] MIP OI-I-Sdn The preparation method comprises the following steps: S1: adding 1.2 g of omeprazole impurity I-Sdn and 240 mg of cobalt chloride to 10 mL of chloroform, shaking for 10 min, standing for 1 h, adding 380 mg of 4-vinylpyridine to the chloroform solution, shaking for 3 min, standing for 0.5 h, and obtaining a polymerized monomer M 4-VP-Co(Ⅱ)-OI-I-Sdn ; S2: Add 4.9g of divinylbenzene and 0.1g of azobisisobutyronitrile to the chloroform solution, shake for 0.5h, pass nitrogen for 0.5h, seal the tube in vacuum, and then polymerize at 60°C for 5h. The polymer product is sieved through a 400-mesh sieve, and the omeprazole impurity I-Sdn molecules are eluted with a solvent until no omeprazole impurity I-Sdn molecules are detected in the washing liquid. Then, the solid product is vacuum dried at 50°C to constant weight to obtain; wherein the solvent is a mixed solvent of methanol and acetic acid.
[0119] The volume ratio of methanol to acetic acid is 6:4.
[0120] The mixed solvent is a mixed solvent of disodium bicarbonate solution and acetonitrile; the volume ratio of the disodium bicarbonate solution to acetonitrile is 6:4.
[0121] The concentration of sodium bicarbonate solution is 0.01 mol / L.
[0122] The preparation method of the quantitative limit solution includes the following steps: S1: taking the sample mother solution into a container, adding the impurity control solution, and then adding n-hexane, shaking and standing to separate the organic phase; S2: adding anhydrous magnesium sulfate, taking the supernatant, and preparing 3 portions in parallel with the same method.
[0123] The spiked concentration of impurities in the quantification limit solution was 22 μg / L.
[0124] The preparation method of the accuracy solution includes the following steps: S1: taking the sample mother solution into a container, adding the impurity reference solution, and then adding n-hexane, shaking and standing to separate the organic phase; S2: adding anhydrous magnesium sulfate, taking the supernatant, and preparing 6 portions in parallel with the same method.
[0125] The spike concentration of impurities in the accuracy solution was 38 μg / L.
[0126] The temperature was raised from 100°C at a rate of 20°C / min to 240°C and maintained for 2 min; then raised to 300°C at a rate of 30°C / min and maintained for 6 min.
[0127] The chromatographic parameters during sample testing are shown in the following table:
[0128]
[0129] The parameters of mass spectrometry during sample detection are shown in the following table:
[0130]
[0131] Precision verification tests include linearity, accuracy, limit of quantitation, and precision-repeatability tests.
[0132] The linear detection process is to take a linear solution for sampling and analysis, and the instrument automatically calculates the regression equation to obtain the correlation coefficient of the equation.
[0133] The accuracy test process is to take sample solution and accuracy solution for analysis, and calculate the recovery rate and relative error.
[0134] The quantitative limit detection process is to take the quantitative limit solution for sampling and analysis, and calculate the recovery rate and relative error.
[0135] Comparative Example 1
[0136] The specific implementation manner of Comparative Example 1 is basically the same as that of Example 1, except that the mixed solvent is a mixed solvent of disodium bicarbonate solution and acetonitrile; and the volume ratio of the disodium bicarbonate solution to acetonitrile is 7:3.
[0137] Comparative Example 2
[0138] The specific implementation method of Comparative Example 2 is basically the same as that of Example 1, except that the mixed solvent is a mixed solvent of sodium bicarbonate solution and acetonitrile; and the volume ratio of the sodium bicarbonate solution to acetonitrile is 4:6.
[0139] Comparative Example 3
[0140] The specific implementation method of Comparative Example 3 is basically the same as that of Example 1, except that the volume ratio of methanol to acetic acid is 4:6.
[0141] Comparative Example 4
[0142] The specific implementation of Comparative Example 4 is basically the same as that of Example 1, except that: OI-I-Sdn The preparation method comprises the following steps: S1: adding 1.444 g of omeprazole impurity I-Sdn and 260 mg of cobalt chloride to 10 mL of chloroform, shaking for 10 min, standing for 1 h, adding 421 mg of 4-vinylpyridine to the chloroform solution, shaking for 3 min, standing for 0.5 h, and obtaining a polymerized monomer M 4-VP-Co(Ⅱ)-OI-I-Sdn ; S2: Add 5.208g of divinylbenzene and 0.1g of azobisisobutyronitrile to the chloroform solution, shake for 0.5h, pass nitrogen for 0.5h, seal the tube in vacuum, and then polymerize at 60°C for 5h. The polymer product is sieved through a 400-mesh sieve, and the omeprazole impurity I-Sdn molecules are eluted with a solvent until no omeprazole impurity I-Sdn molecules are detected in the washing liquid. Then, the solid product is vacuum dried at 50°C to constant weight to obtain; wherein the solvent is a mixed solvent of methanol and acetic acid.
[0143] Performance Evaluation
[0144] Linear equation correlation coefficient: The instrument automatically calculates the regression equation to obtain the correlation coefficient of the equation. The results are recorded in Table 3, where / indicates consistency with the embodiment.
[0145] Accuracy: The sample solution and accuracy solution were injected and analyzed, the recovery rate and relative error (RSD) were calculated, and the precision-repeatability was further tested. The numerical results are recorded in Table 3.
[0146] Limit of quantitation: Take the limit of quantitation solution for analysis, calculate the recovery rate and relative error (RSD), and record the numerical results in Table 3.
[0147] Table 3
[0148]
Claims
1. A quality inspection process for a sodium-magnesium compound chewable tablet, characterized in that: The process includes the following step: S1: Preparation of sample solution; S2: detection of sample solution; S3: precision verification test; The sample solution includes: linear solution, sample mother solution, sample solution, quantitative limit solution, and accuracy solution; The preparation method of the linear solution is: taking impurity control solutions respectively, and making up the volume with organic solvents, and preparing linear solutions according to linear gradients; The concentration of the impurity control solution is 10 mg / L; The impurities are respectively omeprazole impurity I-Sdn, omeprazole impurity II-Snn, omeprazole impurity III-Sss and omeprazole impurity IV-Sds; The linear gradient prepared by the linear solution corresponds to the following: impurity control solution, pipetting volume: 10 μL, fixed volume: 5 mL; impurity control solution, pipetting volume: 20 μL, fixed volume: 5 mL; impurity control solution, pipetting volume: 30 μL, fixed volume: 5 mL; impurity control solution, pipetting volume: 40 μL, fixed volume: 5 mL; impurity control solution, pipetting volume: 50 μL, fixed volume: 5 mL; The impurity concentrations of the linear solutions are 20 μg / L, 40 μg / L, 60 μg / L, 80 μg / L, and 100 μg / L respectively; The method for preparing the sample mother solution comprises the following steps: accurately weighing the Ogilvy sodium magnesium compound chewable tablets and placing them in a volumetric bottle, adding a mixed solvent to dissolve and dilute to 500 mL to obtain the sample mother solution, and preparing 3 portions in parallel by the same method; The method for preparing the sample solution comprises the following steps: S1: adding polymer MIP to the sample mother solution; OI-I-Sdn After adsorption, take out the polymer MIP OI-I-Sdn ; S2: eluted polymer MIP OI-I-Sdn , desorb by shaking, blow dry with nitrogen, then re-dissolve with mixed solvent and make up to 500 mL to obtain sample solution, prepare 3 parts in parallel by the same method; The MIP OI-I-Sdn The preparation method comprises the following steps: S1: adding 1.2 g of omeprazole impurity I-Sdn and 240 mg of cobalt chloride to 10 mL of chloroform, shaking for 10 min, standing for 1 h, adding 380 mg of 4-vinylpyridine to the chloroform solution, shaking for 3 min, standing for 0.5 h, and obtaining a polymerized monomer M 4-VP-Co(Ⅱ)-OI-I-Sdn ; S2: add 4.9g of divinylbenzene and 0.1g of azobisisobutyronitrile to the chloroform solution, shake for 0.5h, pass nitrogen for 0.5h, seal the tube in vacuum, and then polymerize at 60°C for 5h. The polymer product is sieved through a 400-mesh sieve, and the omeprazole impurity I-Sdn molecules are eluted with a solvent until no omeprazole impurity I-Sdn molecules are detected in the washing liquid. Then, the solid product is vacuum dried at 50°C to constant weight to obtain; wherein the solvent is a mixed solvent of methanol and acetic acid; The volume ratio of methanol to acetic acid is 7:3; The mixed solvent is a mixed solvent of disodium bicarbonate solution and acetonitrile; the volume ratio of the disodium bicarbonate solution to acetonitrile is 6:4; The concentration of the sodium bicarbonate solution is 0.01 mol / L; The method for preparing the quantitative limit solution comprises the following steps: S1: taking a sample mother solution into a container, adding an impurity control solution, and then adding n-hexane, shaking and standing, and then separating the organic phase; S2: adding anhydrous magnesium sulfate, taking the supernatant, and preparing 3 portions in parallel by the same method; The spiked concentration of impurities in the quantitative limit solution is 20 μg / L; The method for preparing the accuracy solution comprises the following steps: S1: taking a sample mother solution into a container, adding an impurity reference solution, and then adding n-hexane, shaking and standing, and then separating the organic phase; S2: adding anhydrous magnesium sulfate, taking the supernatant, and preparing 6 portions in parallel by the same method; The spiked concentration of impurities in the accuracy solution is 40 μg / L; The temperature was raised from 100°C at 20°C / min to 240°C, and then maintained for 2 min; then raised to 300°C at 30°C / min, and maintained for 6 min. The parameters of the chromatography during the sample detection process are as follows: injection temperature: 300°C; injection mode: splitless; injection quantity: 1 μL; carrier gas: He; transmission line temperature: 300°C; column flow rate: 1 mL / min; chromatographic column specifications: capillary column with 6% cyanopropylphenyl and 94% dimethylpolysiloxane as stationary liquid; The mass spectrometry parameters during the sample detection process are as follows: ion source temperature: 240°C; quadrupole temperature: 125°C; solvent delay: 5 min; scanning mode: SIM; The precision verification test includes linearity, accuracy, limit of quantitation, and precision-repeatability tests; The linear detection process is to take a linear solution for sampling and analysis, and the instrument automatically calculates the regression equation to obtain the correlation coefficient of the equation; The accuracy detection process is to take sample solution and accuracy solution for injection analysis, and calculate the recovery rate and relative error; The quantitative limit detection process is to take the quantitative limit solution for sampling and analysis, and calculate the recovery rate and relative error.
2. An application of the quality inspection process of the Ogilvy-Sodium-Magnesium Compound Chewable Tablets according to claim 1, characterized in that: The invention comprises the application of the quality inspection process of the omeprazole sodium-magnesium compound chewable tablets in the quality inspection process of the drug chewable tablets.
